43 related articles for article (PubMed ID: 15840387)
1. Validation of the in vitro comet assay for DNA cross-links and altered bases detection.
Muruzabal D; Sanz-Serrano J; Sauvaigo S; Treillard B; Olsen AK; López de Cerain A; Vettorazzi A; Azqueta A
Arch Toxicol; 2021 Aug; 95(8):2825-2838. PubMed ID: 34196753
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of oxidative stress responses in human circulating blood cells after imatinib mesylate treatment - Implications to its mechanism of action.
Gajski G; Gerić M; Domijan AM; Golubović I; Garaj-Vrhovac V
Saudi Pharm J; 2019 Dec; 27(8):1216-1221. PubMed ID: 31885482
[TBL] [Abstract][Full Text] [Related]
3. Co-existence of isodicentric Ph chromosomes and the three-way Ph chromosome variant t(3;9;22)(p21;q34;q11) in a rare case of chronic myeloid leukemia.
Li Q; Lin XJ; Chen H; Gong J; Li Z; Chen XN
Oncol Lett; 2018 Apr; 15(4):4599-4603. PubMed ID: 29541231
[TBL] [Abstract][Full Text] [Related]
4. Triomics Analysis of Imatinib-Treated Myeloma Cells Connects Kinase Inhibition to RNA Processing and Decreased Lipid Biosynthesis.
Breitkopf SB; Yuan M; Helenius KP; Lyssiotis CA; Asara JM
Anal Chem; 2015 Nov; 87(21):10995-1006. PubMed ID: 26434776
[TBL] [Abstract][Full Text] [Related]
5. Influence of selected anti-cancer drugs on the induction of DNA double-strand breaks and changes in gene expression in human hepatoma HepG2 cells.
Novak M; Žegura B; Baebler Š; Štern A; Rotter A; Stare K; Filipič M
Environ Sci Pollut Res Int; 2016 Aug; 23(15):14751-61. PubMed ID: 26392091
[TBL] [Abstract][Full Text] [Related]
6. The role of mitochondrial DNA damage and repair in the resistance of BCR/ABL-expressing cells to tyrosine kinase inhibitors.
Glowacki S; Synowiec E; Blasiak J
Int J Mol Sci; 2013 Aug; 14(8):16348-64. PubMed ID: 23965958
[TBL] [Abstract][Full Text] [Related]
7. BGP-15, a PARP-inhibitor, prevents imatinib-induced cardiotoxicity by activating Akt and suppressing JNK and p38 MAP kinases.
Sarszegi Z; Bognar E; Gaszner B; Kónyi A; Gallyas F; Sumegi B; Berente Z
Mol Cell Biochem; 2012 Jun; 365(1-2):129-37. PubMed ID: 22350755
[TBL] [Abstract][Full Text] [Related]
8. DNA damage and repair in endometrial cancer in correlation with the hOGG1 and RAD51 genes polymorphism.
Krupa R; Sobczuk A; Popławski T; Wozniak K; Blasiak J
Mol Biol Rep; 2011 Feb; 38(2):1163-70. PubMed ID: 20602259
[TBL] [Abstract][Full Text] [Related]
9. BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.
Poplawski T; Blasiak J
Mol Biol Rep; 2010 Jun; 37(5):2309-15. PubMed ID: 19697154
[TBL] [Abstract][Full Text] [Related]
10. [Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia].
Molnár L; Losonczy H
Orv Hetil; 2002 Oct; 143(42):2379-84. PubMed ID: 12440260
[TBL] [Abstract][Full Text] [Related]
11. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
12. Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes.
Czechowska A; Poplawski T; Drzewoski J; Blasiak J
Chem Biol Interact; 2005 Apr; 152(2-3):139-50. PubMed ID: 15840387
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571.
Wozniak K; Czechowska A; Blasiak J
Chem Biol Interact; 2004 Apr; 147(3):309-18. PubMed ID: 15135086
[TBL] [Abstract][Full Text] [Related]
15. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
